Literature DB >> 9479934

Scleral contact lenses.

J M Cotter1, P Rosenthal.   

Abstract

BACKGROUND: Scleral contact lenses provide unique therapeutic and vision rehabilitative properties that overcome the therapeutic gaps encountered with conventional contact lens therapies. CASE REPORTS: Four case reports are presented in which serious visual impairment was remediated with the application of scleral contact lenses: kerataconus, Terriens marginal degeneration, penetrating keratoplasty from Fuchs' dystrophy, and Stevens-Johnson syndrome.
CONCLUSION: The availability of new and diverse materials--in particular, the use of highly oxygen-permeable materials for scleral contact lenses--has allowed reevaluation of the clinical role of scleral lenses in the management of irregular corneal surface disorders and ocular surface disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9479934

Source DB:  PubMed          Journal:  J Am Optom Assoc        ISSN: 0003-0244


  5 in total

1.  A Comparison of Three Methods to Increase Scleral Contact Lens On-Eye Stability.

Authors:  Anita Ticak; Jason D Marsack; Darren E Koenig; Ayeswarya Ravikumar; Yue Shi; Lan Chi Nguyen; Raymond A Applegate
Journal:  Eye Contact Lens       Date:  2015-11       Impact factor: 2.018

2.  Wavefront-guided scleral lens correction in keratoconus.

Authors:  Jason D Marsack; Ayeswarya Ravikumar; Chi Nguyen; Anita Ticak; Darren E Koenig; James D Elswick; Raymond A Applegate
Journal:  Optom Vis Sci       Date:  2014-10       Impact factor: 1.973

3.  Therapeutic use of mini-scleral lenses in a patient with Graves' ophthalmopathy.

Authors:  Jennifer S Harthan
Journal:  J Optom       Date:  2013-01-09

Review 4.  Therapeutic uses of scleral contact lenses for ocular surface disease: patient selection and special considerations.

Authors:  Jennifer S Harthan; Ellen Shorter
Journal:  Clin Optom (Auckl)       Date:  2018-07-11

5.  Prosthetic replacement of the ocular surface ecosystem: impact at 5 years.

Authors:  Joshua S Agranat; Nicole R Kitos; Deborah S Jacobs
Journal:  Br J Ophthalmol       Date:  2015-12-07       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.